Latest Insights VIEW MORE

Consumer Cyclical

Videos,

08 . 13 . 2019

The Future of Hepatitis-B Treatment [ MUST WATCH ]

Consumer Cyclical

Biotechnology, Clinical Trials, FDA, IND,

07 . 18 . 2019

Positive Interim Results from Clinical Trial Offers Hope to Patients with Duchenne Muscular Dystrophy (DMD)

Consumer Cyclical

Biotechnology, Clinical Trials, Industry, Trending,

07 . 16 . 2019

Targeted Immunotherapy – Revigorating The Treatment Of Prostate Cancer

Related Tickers

Recent Events

September 24, 2026 at 12:00 AM UTC

8-A12B: Trading Registrations

September 14, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 9, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 14, 2026 at 12:00 AM UTC

S-4/A: Offering Registrations

July 31, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 30, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 9, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 29, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 22, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Performance

Performance Overview

Trailing total returns as of 9/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMZN
6.87%
S&P 500 (^GSPC)
12.06%

1-Year Return

AMZN
11.03%
S&P 500 (^GSPC)
15.16%

3-Year Return

AMZN
94.04%
S&P 500 (^GSPC)
78.89%

5-Year Return

AMZN
49.45%
S&P 500 (^GSPC)
75.96%

Financials

Research

Videos,
Consumer Cyclical

The Future of Hepatitis-B Treatment [ MUST WATCH ]

Biotechnology, Clinical Trials, FDA, IND,
Consumer Cyclical

Positive Interim Results from Clinical Trial Offers Hope to Patients with Duchenne Muscular Dystrophy (DMD)

Biotechnology, Clinical Trials, Industry, Trending,
Consumer Cyclical

Targeted Immunotherapy – Revigorating The Treatment Of Prostate Cancer

Analysis

Earnings Estimate

GAAP
Normalized
Currency in USD
Current Qtr. (Sep 2026)
Next Qtr. (Dec 2026)
Current Year (2026)
Next Year (2027)
No. of Analysts 44 41 50 52
Avg. Estimate 1.95 2.44 12.88 10.5
Low Estimate 1.72 2 12.15 8.73
High Estimate 2.23 2.75 13.51 15.04
Year Ago EPS 1.95 1.95 7.17 12.88

Revenue Estimate

Currency in USD
Current Qtr. (Sep 2026)
Next Qtr. (Dec 2026)
Current Year (2026)
Next Year (2027)
No. of Analysts 46 44 55 57
Avg. Estimate 202.07B 244.05B 828.37B 947.93B
Low Estimate 199.37B 234.24B 815.87B 898.02B
High Estimate 207.68B 255.93B 841.98B 992.15B
Year Ago Sales 180.17B 213.39B 716.92B 828.37B
Sales Growth (year/est) 12.15% 14.37% 15.54% 14.43%

Earnings History

GAAP
Normalized
Currency in USD
9/30/2025
12/31/2025
3/31/2026
6/30/2026
EPS Est. 1.56 1.96 1.65 1.83
EPS Actual 1.95 1.95 2.78 5.75
Difference 0.39 -0.01 1.13 3.92
Surprise % 25.20% -0.49% 68.18% 214.89%

EPS Trend

GAAP
Normalized
Currency in USD
Current Qtr. (Sep 2026)
Next Qtr. (Dec 2026)
Current Year (2026)
Next Year (2027)
Current Estimate 1.95 2.44 12.88 10.5
7 Days Ago 1.95 2.44 12.88 10.48
30 Days Ago 1.95 2.44 12.81 10.49
60 Days Ago 1.96 2.39 8.72 10.01
90 Days Ago 1.92 2.38 8.68 9.97

EPS Revisions

GAAP
Normalized
Currency in USD
Current Qtr. (Sep 2026)
Next Qtr. (Dec 2026)
Current Year (2026)
Next Year (2027)
Up Last 7 Days 1 1 2 2
Up Last 30 Days 4 4 7 8
Down Last 7 Days -- 1 -- --
Down Last 30 Days 1 2 1 1

Growth Estimates

Symbol Current Qtr.Next Qtr.Current YearNext Year
AMZN 1.33%23.28%13.64%28.56%
S&P 500 49.87%23.81%31.75%34.40%